Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions
Summary The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infec...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2009-10, Vol.9 (10), p.617-624 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 624 |
|---|---|
| container_issue | 10 |
| container_start_page | 617 |
| container_title | The Lancet infectious diseases |
| container_volume | 9 |
| creator | Moise, Pamela A, PharmD North, Donald, PharmD Steenbergen, Judith N, PhD Sakoulas, George, Dr |
| description | Summary The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infections. Understanding the clinical importance of the microbiological effects of glycopeptides on bacterial lipopeptides and lipoglycopeptides will be crucial in treating serious meticillin-resistant S aureus infections. We review the observed effects of reduced glycopeptide susceptibility on the activities of daptomycin in S aureus in vitro and in vivo. Factors associated with loss of susceptibility and ways to reduce the risk of resistance to daptomycin are reviewed, including the importance of prompt mechanical reduction of bacterial inoculum through surgery or through potent or combination antibiotic therapy, as well as optimisation of daptomycin pharmacodynamic exposure. |
| doi_str_mv | 10.1016/S1473-3099(09)70200-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67664091</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1473309909702002</els_id><sourcerecordid>67664091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-304d90839ba47be18455fe0d8377854a6e79edf44db6c1c7e31bd02dce3ec61c3</originalsourceid><addsrcrecordid>eNqFkV2L1TAQhoMo7u7Rn6AUwUUvqkmaJo0Xiix-wYIXR69DmkzZrD1pN0lX-u_NacsKe7MQmEx45p2ZvAi9IPgdwYS_3xMmqrLCUr7B8q3AFOOSPkKn-ZmVjNXi8XJfkRN0FuM1xkQQzJ6iEyKFaARnp8jvp2hgTK51vUtzEaDXyQ0-XrmxaCH9BfDFrfZmOMzG-UJ7W1g9pi3NZ5_0eDX3gxmMmWKhpwA5fCg6bVJceB3jdBgX1WfoSaf7CM-3uEO_v375dfG9vPz57cfF58vS1IKmPDOzEjeVbDUTLZCG1XUH2DZVnrtmmoOQYDvGbMsNMQIq0lpMrYEKDCem2qHzVXcMw80EMamDy3v2vfYwTFFxwTnDkjwIUkKaKnfN4Kt74PUwBZ-XUBSTWjQ8cztUr5AJQ4wBOjUGd9BhVgSro21qsU0dPVFYqsU2RXPdy018ag9g_1dtPmXg9QboaHTfheyIi3ccJbKpucSZ-7RykD_31kFQ0TjwBqwLYJKyg3twlI_3FEzvvMtN_8AM8W5poiJVeBU5amC5KNDqH7HqysQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201578683</pqid></control><display><type>article</type><title>Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Moise, Pamela A, PharmD ; North, Donald, PharmD ; Steenbergen, Judith N, PhD ; Sakoulas, George, Dr</creator><creatorcontrib>Moise, Pamela A, PharmD ; North, Donald, PharmD ; Steenbergen, Judith N, PhD ; Sakoulas, George, Dr</creatorcontrib><description>Summary The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infections. Understanding the clinical importance of the microbiological effects of glycopeptides on bacterial lipopeptides and lipoglycopeptides will be crucial in treating serious meticillin-resistant S aureus infections. We review the observed effects of reduced glycopeptide susceptibility on the activities of daptomycin in S aureus in vitro and in vivo. Factors associated with loss of susceptibility and ways to reduce the risk of resistance to daptomycin are reviewed, including the importance of prompt mechanical reduction of bacterial inoculum through surgery or through potent or combination antibiotic therapy, as well as optimisation of daptomycin pharmacodynamic exposure.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(09)70200-2</identifier><identifier>PMID: 19778764</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Biological and medical sciences ; daptomycin ; Daptomycin - pharmacology ; Glycopeptides ; Human bacterial diseases ; Humans ; Infection ; Infectious Disease ; Infectious diseases ; Inoculum ; lipopeptides ; Medical sciences ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Pharmacodynamics ; Pharmacology. Drug treatments ; Reviews ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; Staphylococcal Infections - surgery ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Surgery ; Vancomycin ; Vancomycin - pharmacology ; Vancomycin Resistance</subject><ispartof>The Lancet infectious diseases, 2009-10, Vol.9 (10), p.617-624</ispartof><rights>Elsevier Ltd</rights><rights>2009 Elsevier Ltd</rights><rights>2009 INIST-CNRS</rights><rights>Copyright Elsevier Limited Oct 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c572t-304d90839ba47be18455fe0d8377854a6e79edf44db6c1c7e31bd02dce3ec61c3</citedby><cites>FETCH-LOGICAL-c572t-304d90839ba47be18455fe0d8377854a6e79edf44db6c1c7e31bd02dce3ec61c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309909702002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21985690$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19778764$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moise, Pamela A, PharmD</creatorcontrib><creatorcontrib>North, Donald, PharmD</creatorcontrib><creatorcontrib>Steenbergen, Judith N, PhD</creatorcontrib><creatorcontrib>Sakoulas, George, Dr</creatorcontrib><title>Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infections. Understanding the clinical importance of the microbiological effects of glycopeptides on bacterial lipopeptides and lipoglycopeptides will be crucial in treating serious meticillin-resistant S aureus infections. We review the observed effects of reduced glycopeptide susceptibility on the activities of daptomycin in S aureus in vitro and in vivo. Factors associated with loss of susceptibility and ways to reduce the risk of resistance to daptomycin are reviewed, including the importance of prompt mechanical reduction of bacterial inoculum through surgery or through potent or combination antibiotic therapy, as well as optimisation of daptomycin pharmacodynamic exposure.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>daptomycin</subject><subject>Daptomycin - pharmacology</subject><subject>Glycopeptides</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infection</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Inoculum</subject><subject>lipopeptides</subject><subject>Medical sciences</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Pharmacodynamics</subject><subject>Pharmacology. Drug treatments</subject><subject>Reviews</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcal Infections - surgery</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Surgery</subject><subject>Vancomycin</subject><subject>Vancomycin - pharmacology</subject><subject>Vancomycin Resistance</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkV2L1TAQhoMo7u7Rn6AUwUUvqkmaJo0Xiix-wYIXR69DmkzZrD1pN0lX-u_NacsKe7MQmEx45p2ZvAi9IPgdwYS_3xMmqrLCUr7B8q3AFOOSPkKn-ZmVjNXi8XJfkRN0FuM1xkQQzJ6iEyKFaARnp8jvp2hgTK51vUtzEaDXyQ0-XrmxaCH9BfDFrfZmOMzG-UJ7W1g9pi3NZ5_0eDX3gxmMmWKhpwA5fCg6bVJceB3jdBgX1WfoSaf7CM-3uEO_v375dfG9vPz57cfF58vS1IKmPDOzEjeVbDUTLZCG1XUH2DZVnrtmmoOQYDvGbMsNMQIq0lpMrYEKDCem2qHzVXcMw80EMamDy3v2vfYwTFFxwTnDkjwIUkKaKnfN4Kt74PUwBZ-XUBSTWjQ8cztUr5AJQ4wBOjUGd9BhVgSro21qsU0dPVFYqsU2RXPdy018ag9g_1dtPmXg9QboaHTfheyIi3ccJbKpucSZ-7RykD_31kFQ0TjwBqwLYJKyg3twlI_3FEzvvMtN_8AM8W5poiJVeBU5amC5KNDqH7HqysQ</recordid><startdate>20091001</startdate><enddate>20091001</enddate><creator>Moise, Pamela A, PharmD</creator><creator>North, Donald, PharmD</creator><creator>Steenbergen, Judith N, PhD</creator><creator>Sakoulas, George, Dr</creator><general>Elsevier Ltd</general><general>Lancet Publishing Group</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T7</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20091001</creationdate><title>Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions</title><author>Moise, Pamela A, PharmD ; North, Donald, PharmD ; Steenbergen, Judith N, PhD ; Sakoulas, George, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-304d90839ba47be18455fe0d8377854a6e79edf44db6c1c7e31bd02dce3ec61c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>daptomycin</topic><topic>Daptomycin - pharmacology</topic><topic>Glycopeptides</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infection</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Inoculum</topic><topic>lipopeptides</topic><topic>Medical sciences</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Pharmacodynamics</topic><topic>Pharmacology. Drug treatments</topic><topic>Reviews</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcal Infections - surgery</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Surgery</topic><topic>Vancomycin</topic><topic>Vancomycin - pharmacology</topic><topic>Vancomycin Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moise, Pamela A, PharmD</creatorcontrib><creatorcontrib>North, Donald, PharmD</creatorcontrib><creatorcontrib>Steenbergen, Judith N, PhD</creatorcontrib><creatorcontrib>Sakoulas, George, Dr</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moise, Pamela A, PharmD</au><au>North, Donald, PharmD</au><au>Steenbergen, Judith N, PhD</au><au>Sakoulas, George, Dr</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2009-10-01</date><risdate>2009</risdate><volume>9</volume><issue>10</issue><spage>617</spage><epage>624</epage><pages>617-624</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary The decrease in vancomycin treatment efficacy that is accompanying increases in vancomycin minimum inhibitory concentration (MIC) within the susceptible range (so-called MIC creep) has led to the suggestion that vancomycin is losing its potency in treating serious Staphylococcus aureus infections. Understanding the clinical importance of the microbiological effects of glycopeptides on bacterial lipopeptides and lipoglycopeptides will be crucial in treating serious meticillin-resistant S aureus infections. We review the observed effects of reduced glycopeptide susceptibility on the activities of daptomycin in S aureus in vitro and in vivo. Factors associated with loss of susceptibility and ways to reduce the risk of resistance to daptomycin are reviewed, including the importance of prompt mechanical reduction of bacterial inoculum through surgery or through potent or combination antibiotic therapy, as well as optimisation of daptomycin pharmacodynamic exposure.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>19778764</pmid><doi>10.1016/S1473-3099(09)70200-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2009-10, Vol.9 (10), p.617-624 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67664091 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biological and medical sciences daptomycin Daptomycin - pharmacology Glycopeptides Human bacterial diseases Humans Infection Infectious Disease Infectious diseases Inoculum lipopeptides Medical sciences Microbial Sensitivity Tests Minimum inhibitory concentration Pharmacodynamics Pharmacology. Drug treatments Reviews Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Staphylococcal Infections - surgery Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus aureus Staphylococcus aureus - drug effects Surgery Vancomycin Vancomycin - pharmacology Vancomycin Resistance |
| title | Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A44%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Susceptibility%20relationship%20between%20vancomycin%20and%20daptomycin%20in%20Staphylococcus%20aureus%20:%20facts%20and%20assumptions&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Moise,%20Pamela%20A,%20PharmD&rft.date=2009-10-01&rft.volume=9&rft.issue=10&rft.spage=617&rft.epage=624&rft.pages=617-624&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(09)70200-2&rft_dat=%3Cproquest_cross%3E67664091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201578683&rft_id=info:pmid/19778764&rft_els_id=S1473309909702002&rfr_iscdi=true |